Palisade Bio Advances IBD Drug into Phase 2 Trials with Strong Financial Backing — Palisade Bio, Inc.

Event summary

Palisade Bio expects to enroll the first patient in its Phase 2 ASCENTRA-UC trial for PALI-2108 in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.
The company plans to submit an IND application for the Phase 2 ASCENTRA-CD trial in the second half of 2026, targeting a trial start in early 2027 and primary efficacy readout in early 2028.
Palisade Bio reported $125.2 million in cash and cash equivalents as of June 30, 2026, sufficient to fund operations through key clinical milestones.
Phase 1 trial results showed favorable safety and tolerability for PALI-2108, with clinical response in all UC patients and significant reduction in SES-CD score for Crohn’s disease patients.

The big picture

Palisade Bio is advancing its lead candidate, PALI-2108, into Phase 2 trials for inflammatory bowel disease (IBD), targeting both ulcerative colitis and Crohn’s disease. The company’s strong financial position supports its ability to execute through key clinical milestones, positioning it as a potential disruptor in the IBD treatment landscape. The strategic focus on targeted prodrug technology aims to address unmet needs in a market where many patients fail to achieve durable remission with existing therapies.

What we're watching

Clinical Progress: The pace at which Palisade Bio can enroll patients and generate Phase 2 data for PALI-2108 will determine its competitive positioning in the IBD market.
Financial Sustainability: Whether Palisade Bio’s current cash reserves will be sufficient to support operations through 2028, given the anticipated timeline for key clinical readouts.
Regulatory Approval: How the FDA’s review of the IND application and subsequent trial data could impact the approval pathway for PALI-2108 in both UC and Crohn’s disease indications.